A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Table of Contents SUMMARY OF PRINCIPAL RISK FACTORS This summary briefly lists the principal risks and uncertainties facing our business, which are only a select portion of those risks. A more complete discussion of those risks and uncertainties is set forth in Part I, Item 1A of this Annual Report on Form 10-K, entitled “Risk Factors.” Additional risks not presently known to us or that we currently deem immaterial may also affect us. If any of these risks occur, our business, financial condition or results of operations could be materially and adversely affected. Our business is subject to the following principal risks and uncertainties: •We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future as we continue development and, subject to positive data and regulatory approval, the commercialization of our product candidates. •We currently have no source of product revenues.
| Metric | TTM | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | - | - | 0 |
| Net Income | -26M | -37M | -41M | -21M | -17M | -28M |
| EPS | $-0.28 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | $-10.92 |
| Free Cash Flow | 0 | -31M | -24M | -26M | -10M | -18M |
| ROIC | -1624.4% | -481.1% | -683.2% | -98.2% | -60.2% | -259.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -1.78 | 3.32 | 0.29 | 0.65 | 1.73 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -27M | -38M | -42M | -25M | -17M | -20M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -56.9% | - | -851.4% | -101.7% | -60.2% | -458.7% |
| Shares Outstanding | 142M | 28M | 19M | 15M | 8M | 15M |
SELLAS Life Sciences Group, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
SELLAS Life Sciences Group, Inc. (SLS) has a 5-year average return on invested capital (ROIC) of -79.2%. This is below average and may indicate limited pricing power.
SELLAS Life Sciences Group, Inc. (SLS) has a market capitalization of $678M. It is classified as a small-cap stock.
SELLAS Life Sciences Group, Inc. (SLS) does not currently pay a regular dividend.
SELLAS Life Sciences Group, Inc. (SLS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
SELLAS Life Sciences Group, Inc. (SLS) generated $-31 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
SELLAS Life Sciences Group, Inc. (SLS) reported earnings per share (EPS) of $-1.34 in its most recent fiscal year.
The Ledger Terminal provides 10 years of financial data for SELLAS Life Sciences Group, Inc. (SLS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
SELLAS Life Sciences Group, Inc. (SLS) has a book value per share of $-0.29, based on its most recent annual SEC filing.